ADVERTISEMENT

Ajanta Pharma Q3 Results Review: Systematix Upgrades The Stock To 'Buy', Revises Target Price — Here's Why

The brokerage revises its target PE multiple to 35 times FY27E EPS and upgrade Ajanta to Buy at current market price with a revised target price of Rs 3,460.

Systematix Institutional Equities

31 Jan 2025, 10:42 AM IST i

<div class="paragraphs"><p>Ajanta Pharma Ltd. Q3 FY25 revenue came slightly below expectation, while Ebitda and PAT were largely in line.</p><p>(Photo Source: Milivigerova/ pexels)</p></div>

Ajanta Pharma Ltd. Q3 FY25 revenue came slightly below expectation, while Ebitda and PAT were largely in line.

(Photo Source: Milivigerova/ pexels)

Ajanta Pharma remains on track to deliver low to mid teens growth in branded market and mid-single digit growth in the US generic space for FY25.

OUR NEWSLETTERS

Sign Up

By signing up you agree to the Terms & Conditions of NDTV Profit